Advair Reduces Exacerbations In COPD Patients

The use of Advair Diskus 250/50 (fluticasone propionate and salmeterol inhalation powder) demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations as compared with salmeterol alone, according to new data presented today at the International Conference of the American Thoracic Society meeting in Toronto.